Skip to content

Pharmacokinetics Ertapenem Burns

Pharmacokinetics of Ertapenem When Used in Empiric Treatment in Burn Patients. Prospective Open Label Study.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01497990
Enrollment
8
Registered
2011-12-23
Start date
2010-01-01
Completion date
2011-09-01
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Patients

Keywords

Burns, Ertapenem, Pharmacokinetics

Brief summary

This study will examine the pharmacokinetics of ertapenem in ventilated badly (\> 30% SCT) burn patients.

Interventions

DRUGErtapenem

The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 to 70 years * Burned on 30 to 60% of their body surface * Mechanical ventilation * Hospitalized in the intensive care unit of Nantes University Hospital for less than 8 days. * Which the family gave consent * insured

Exclusion criteria

* Patients whose family refused to sign the consent for participation. * Patients allergic to beta lactam * Patients with renal failure with creatinine clearance \<80 ml.mn-1 * Pregnant women * Persons protected by the law

Design outcomes

Primary

MeasureTime frameDescription
Measurement of serum concentrations of total ertapenem from the second injection in order to calculate Cmax, Vz, ClP , ClR , ClNR , fe, T1/2b et AUC0 - alpha.Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injectionCurrent study the pharmacokinetics (Cmax, Vz, ClP , ClR , ClNR , fe, T1/2beta, AUC 0 - alpha) in a population of burn patients.

Secondary

MeasureTime frameDescription
Time between injection and observation of a serum concentration less than the critical concentration belowBlood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injectionCheck that the injection of 1 g ertapenem achieves a serum concentration above the critical concentration of bacteria usually isolated in cases of early infection for more than 40% of the time between two injections (t / MIC\> 40 %), this ratio being one of the criteria predictive of efficacy of beta-lactam antibiotics.
Time needed between injections in order to obtain a concentration greater than the critical concentration below for the duration of time between two injectionsBlood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injectionStudy when two injections of ertapenem serum concentrations fall below the critical concentrations of bacteria usually isolated in cases of early infection, if they become.

Countries

France

Contacts

STUDY_CHAIRRonan LE FLOCH, PH

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026